OncoMatch/Clinical Trials/NCT06627244
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Is NCT06627244 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tebentafusp for metastatic uveal melanoma.
Treatment: Tebentafusp — The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Required: HLA-A A*02:01 positive
Human leukocyte antigen-A*02:01(HLA A⁕ 02:01) positive
Disease stage
Required: Stage IV
Metastatic disease required
Metastatic uveal melanoma, confined mainly to the liver
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radioembolization or other regional, liver-directed therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1.0 × 10^9 cells/L; Absolute lymphocyte count < 0.5 × 10^9 cells/L; Platelet count < 75 × 10^9 platelets/L; Hemoglobin < 8 g/dL
Liver function
Serum bilirubin <2 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN); Exclusion: Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome, who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN; ALT > 3 × ULN; AST > 3 × ULN
Cardiac function
Clinically significant cardiac disease or impaired cardiac function, including: congestive heart failure (NYHA Class ≥ 3), uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 110 mmHg), history of ventricular arrhythmia currently requiring medical treatment, uncontrolled atrial fibrillation, ECG QTcF > 470 msec or known history of congenital prolonged QT syndrome, acute myocardial infarction or unstable angina pectoris ≤ 6 months prior to screening
Serum bilirubin <2 mg/dl, AST and ALT < 5 x ULN; Exclusion: Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome, who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN; ALT > 3 × ULN; AST > 3 × ULN; ANC < 1.0 × 10^9 cells/L; Absolute lymphocyte count < 0.5 × 10^9 cells/L; Platelet count < 75 × 10^9 platelets/L; Hemoglobin < 8 g/dL; Cardiac disease as detailed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify